Identification of inhibitors of the Salmonella F ra B deglycase, a drug target
FEBS Open Bio · 2025
DOI: 10.1002/2211-5463.70001 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, 2025. Verfasst von Jamison D Law und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA. Hauptthemen laut MEDLINE: Bacterial Proteins, Anti-Bacterial Agents, Salmonella, Enzyme Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of Allergy and Infectious Diseases, NIH HHS.
Abstract (Originalsprache)
Nontyphoidal Salmonella is one of the most prevalent causes of human foodborne illnesses worldwide, with no narrow‐spectrum antibiotics or vaccines available. Here, we seek to address this gap. During the host inflammatory response, Salmonella metabolizes fructose‐asparagine as a nutrient using proteins encoded in the fra operon. Deletion of fraB leads to a build‐up of 6‐phosphofructose‐aspartate, the substrate of FraB, and intoxicates Salmonella . Because fra genes are absent in mammals and most members of the human gut microbiome, FraB inhibitors are expected to have limited off‐target effects and offer prospects as potential therapeutics. To identify such inhibitors, we conducted a high‐throughput screening of small‐molecule libraries using a FraB activity‐based biochemical assay. We screened 131,165 compounds and identified 126 hits that could be obtained commercially for further characterization. When tested at 25 μ m inhibitor in the presence of 1 m m 6‐phosphofructose‐aspartate, FraB activity was reduced ~ 30–100% by 65 compounds. Guided by preliminary cell‐based data, we further characterized six compounds (one triazolidine, two thiadiazolidines, and three triazolothiadiazoles) and found them to exhibit IC 50 values from ~ 3 to 100 μ m and K I (inhibitor constant) values from ~ 1 to 29 μ m . Native mass spectrometry revealed that all three triazolothiadiazoles were capable of binding FraB; we also obtained evidence that one of the triazolothiadiazoles binds FraB even in the presence of substrate. The recurrence of multiple pharmacophores bolsters prospects for farming more hits from compound libraries and for designing therapeutics against nontyphoidal Salmonella .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.
- Native Mass Spectrometry Guided Structural Biology Center, The Ohio State University, Columbus, OH, USA.
- Department of Microbiology, The Ohio State University, Columbus, OH, USA.
- Center for RNA Biology, The Ohio State University, Columbus, OH, USA.
- Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.
ORCID-Profile: Venkat Gopalan
Förderung
- NIGMS NIH HHS
- National Institute of Allergy and Infectious Diseases
- NIH HHS
- Ohio State University College of Medicine
- Ohio State University Comprehensive Cancer Center
- National Institute of General Medical Sciences
- National Institutes of Health
Zitieren
APA
Law, J. D., Gao, Y., Kovvali, S., Thirugnanasambantham, P., Wysocki, V. H., Ahmer, B. M. M., & Gopalan, V. (2025). Identification of inhibitors of the Salmonella F ra B deglycase, a drug target. FEBS Open Bio. https://doi.org/10.1002/2211-5463.70001
Vancouver
Law JD, Gao Y, Kovvali S, Thirugnanasambantham P, Wysocki VH, Ahmer BMM, et al. Identification of inhibitors of the Salmonella F ra B deglycase, a drug target. FEBS Open Bio. 2025. doi:10.1002/2211-5463.70001
BibTeX
@article{Law2025,
author = {Law, Jamison D and Gao, Yuan and Kovvali, Sravya and Thirugnanasambantham, Pankajavalli and Wysocki, Vicki H and Ahmer, Brian M M and Gopalan, Venkat},
title = {Identification of inhibitors of the Salmonella F ra B deglycase, a drug target},
journal = {FEBS Open Bio},
year = {2025},
doi = {10.1002/2211-5463.70001}
}
EUVIMED